Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early familial non-medullary thyroid cancer: differences with late-onset and sporadic forms.

European journal of endocrinology·2026
Same author

Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression.

The Journal of clinical endocrinology and metabolism·2026
Same author

Detection of Central Compartment Lymph Node Metastasis of Thyroid Cancer: Usefulness of Intraoperative Thyroglobulin Measurement in Fine Needle Aspiration Washout with and Without Blue Dye Injection.

Cancers·2025
Same author

Subclinical Ocular Motility Dysfunction and Extraocular Muscle Changes in Inactive Graves' Orbitopathy.

Journal of personalized medicine·2024
Same author

Diffuse C-Cells Hyperplasia Is the Source of False Positive Calcitonin Measurement in FNA Washout Fluids of Thyroid Nodules: A Rational Clinical Approach to Avoiding Unnecessary Surgery.

Cancers·2024
Same author

Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?

International journal of molecular sciences·2023

Related Experiment Videos

Cardiovascular risk in elderly hypothyroid patients.

Stefano Mariotti1, Valentina Maria Cambuli

  • 1Endocrinology, Department of Medical Sciences M. Aresu, University of Cagliari, Policlinico Universitario di Monserrato, Monserrato, Cagliari, Italy. mariotti@pacs.unica.it

Thyroid : Official Journal of the American Thyroid Association
|December 1, 2007
PubMed
Summary

Overt hypothyroidism (OH) and subclinical hypothyroidism (SH) impact cardiovascular health. While levothyroxine (L-T4) treatment benefits OH, SH

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Cardiology
  • Geriatrics

Background:

  • Overt hypothyroidism (OH) and subclinical hypothyroidism (SH) are common in the elderly.
  • OH is linked to cardiovascular issues like hypertension, atherogenic lipid profiles, increased arterial stiffness, and endothelial dysfunction.
  • SH presents milder cardiovascular abnormalities, but its health impact remains debated.

Purpose of the Study:

  • To review the cardiovascular implications of OH and SH in the elderly.
  • To discuss the benefits of levothyroxine (L-T4) replacement therapy for OH.
  • To examine the evidence and controversies surrounding the screening and treatment of SH.

Main Methods:

  • Review of existing literature on hypothyroidism and cardiovascular disease.
  • Analysis of epidemiological studies and meta-analyses on SH and cardiovascular risk.
  • Discussion of age-specific effects of thyroid dysfunction and treatment.

Main Results:

  • Cardiovascular benefits of L-T4 therapy in OH are well-established.
  • SH is associated with a slight but significant increase in coronary heart disease (CHD) risk.
  • Evidence suggests SH may increase cardiovascular risk in middle-aged and younger elderly, but may be protective in the oldest-old (>85 years).

Conclusions:

  • L-T4 therapy is beneficial for OH regardless of age or comorbidities.
  • Consensus on SH screening and treatment is lacking, with potential risks in the elderly.
  • Thyroid dysfunction's impact varies by age, necessitating further research for tailored management strategies.